Abstract
Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have